Liquidia (LQDA) Earnings Date & Reports

Key Takeaways

• Third quarter 2026 total revenue reached $225.3 million, up sharply from $54.34 million in the same period a year earlier, driven almost entirely by YUTREPIA.
• YUTREPIA net product sales totaled roughly $222.7 million, up about 31% sequentially from the second quarter of 2026.
• GAAP (generally accepted accounting principles) net loss was $236.3 million, or $2.64 per share, reflecting a roughly $389.7 million litigation settlement charge tied to United Therapeutics.
• Non-GAAP adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) was approximately $140.5 million, the fifth consecutive quarter of sequential improvement.
• A global settlement narrows YUTREPIA's approved use to PAH (pulmonary arterial hypertension) and commits about $380.7 million in cash payments through April 2027.
• Cash and cash equivalents ended the quarter at approximately $396 million, before settlement-related outlays are fully reflected.
• For more information on this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Explore Trending AI Robots to see automated strategies and market signals powered by artificial intelligence.

Earnings Context and Why It Matters

Liquidia Corporation is a biopharmaceutical company focused on rare cardiopulmonary conditions, led by its inhaled treprostinil product YUTREPIA. Approved by the U.S. Food and Drug Administration (FDA) in May 2025 and launched commercially in June 2025, YUTREPIA has rapidly become the company's dominant revenue driver. The third quarter of 2026 is significant because it captures a maturing commercial launch while also being the first report after a major patent ruling and global settlement with United Therapeutics. For investors, the quarter tests whether strong sales momentum can coexist with a narrower label and a substantial cash commitment, making this earnings recap a key checkpoint for Liquidia's long-term growth story.

Reported Results

Liquidia reported total revenue of $225.3 million for the third quarter ended September 30, 2026, compared with $54.34 million a year earlier. YUTREPIA net product sales were approximately $222.7 million, up about 31% sequentially. Revenue came in ahead of consensus expectations, while reported GAAP results were dominated by a one-time charge.

The company recorded a GAAP net loss of $236.3 million, or $2.64 per share, versus a net loss of $3.53 million, or $0.04 per share, in the prior-year quarter. The swing was driven by a roughly $389.7 million litigation settlement charge. Excluding that item, non-GAAP adjusted EBITDA was approximately $140.5 million, the fifth straight quarter of sequential growth, with adjusted earnings around $0.80 per share.

Management also disclosed that the previously repeated $1 billion 2027 revenue target has been retired, with a clearer guidance update now expected in January 2027.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following Liquidia and similar names, it offers a structured way to surface actionable setups and compare opportunities across the broader market.

Market Reaction and Investor Sentiment

Liquidia shares have been volatile around this earnings cycle. After an October 1, 2026 federal court ruling that certain patent claims covering inhaled treprostinil for PH-ILD (pulmonary hypertension associated with interstitial lung disease) were valid and infringed, the stock fell to a 52-week low of $22.31. It subsequently rebounded roughly 115% from that low as the October 13 global settlement with United Therapeutics removed the worst-case disruption scenario.

Heading into the report, sentiment had cooled from mildly positive to roughly neutral, reflecting the settlement's trade-offs: YUTREPIA remains on the market without interruption, but its label is now limited to PAH and the company has committed significant cash. Post-report, investors are weighing strong commercial execution and expanding adjusted EBITDA margins against the reduced size of the addressable market.

Forward Outlook and Key Factors to Monitor

The most important near-term catalyst is the January 2027 guidance update, which will clarify how much growth management expects under the PAH-only label. Investors will also watch how the roughly $380.7 million settlement liability, payable in installments through April 2027, affects the balance sheet and operating flexibility.

Commercially, key metrics to monitor include YUTREPIA patient additions, payer access, and whether the company can continue converting referrals into prescriptions at the high rates seen during launch. Adjusted EBITDA margin expansion will signal whether the business can sustain profitability while absorbing the settlement costs.

On the pipeline side, the next-generation inhaled therapy L606 represents a longer-term growth lever, and its development costs are a factor in research and development spending. Industry competition in the prostacyclin space also remains a watch item. Overall, the story has shifted from pure launch momentum to execution within a narrower but still substantial commercial opportunity.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations